Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Other Working Capital Changes (2016 - 2025)

Marimed (MRMD) has disclosed Other Working Capital Changes for 12 consecutive years, with $321000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes fell 38.97% to $321000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$209000.0, a 92.7% increase, with the full-year FY2024 number at -$883000.0, up 80.38% from a year prior.
  • Other Working Capital Changes was $321000.0 for Q3 2025 at Marimed, up from $189000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $3.2 million in Q4 2022 to a low of -$3.5 million in Q3 2023.
  • A 5-year average of $51263.2 and a median of $268000.0 in 2021 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: skyrocketed 4368.18% in 2021, then crashed 600.99% in 2023.
  • Marimed's Other Working Capital Changes stood at -$773000.0 in 2021, then surged by 519.92% to $3.2 million in 2022, then crashed by 175.79% to -$2.5 million in 2023, then soared by 80.53% to -$479000.0 in 2024, then surged by 167.01% to $321000.0 in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Other Working Capital Changes are $321000.0 (Q3 2025), $189000.0 (Q2 2025), and -$240000.0 (Q1 2025).